Otonomy to Present at Two Upcoming Investor Conferences – MarketWatch

Otonomy to Present at Two Upcoming Investor ConferencesMarketWatchOTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com. CONTACT: Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Vice President 619.849.5377 …and more »